Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 3 5Phase 1/2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Dermatologic 1

Conditions

Lung Neoplasms 4Sezary Syndrome 3Mycosis Fungoides 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, T-Cell 1Gliosarcoma 1Glioma 1Glioblastoma 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Colitis 1Cholangiocarcinoma 1Cervical Adenocarcinoma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × Disulfides × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02581787 2024-03-27

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Stanford University

Phase 1/2 Completed
28 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡